Literature DB >> 121041

Inhibition of purine nucleoside phosphorylase activity and of T-cell function with allopurinol-riboside.

Y Nishida, N Kamatani, K Tanimoto, I Akaoka.   

Abstract

Allopurinol-riboside competitively inhibits the action of purine nucleoside phosphorylase on inosine in vitro with a Ki of 277 mumol. After simple incubation of allopurinol-riboside with PNP, allopurinol was not formed. Lymphocyte blastogensis induced by PHA and Con A was significantly suppressed by allopurinol-riboside in a concentration-dependent manner. When LPS was used as a mitogen, the inhibition of allopurinol-riboside on lymphocyte proliferation was less marked. Humoral immunity was not suppressed by allopurinol-riboside. In contrast, cellular immunity was significantly suppressed by allopurinol-riboside in vivo. These results suggested that allopurinol-riboside is a drug which produces a model of PNP deficiency, and that it may be a useful inhibitor of cellular immunity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 121041     DOI: 10.1007/bf01968126

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  13 in total

1.  Adenosine deaminase from human erythrocytes: purification and effects of adenosine analogs.

Authors:  R P Agarwal; S M Sagar; R E Parks
Journal:  Biochem Pharmacol       Date:  1975-03-15       Impact factor: 5.858

2.  Deoxyguanosine toxicity in a mouse T lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction.

Authors:  L J Gudas; B Ullman; A Cohen; D W Martin
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

3.  Influence of dose and route of antigen injection on the immunological induction of T cells.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

4.  Absence of erythrocyte adenosine deaminase associated with severe combined immunodeficiency.

Authors:  J Yount; P Nichols; H D Ochs; S P Hammar; C R Scott; S H Chen; E R Giblett; R J Wedgwood
Journal:  J Pediatr       Date:  1974-02       Impact factor: 4.406

5.  Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis.

Authors:  D A Carson; J E Seegmiller
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

6.  Control of pyrimidine biosynthesis in human lymphocytes. Inhibitory effect of guanine and guanosine on induction of enzymes for pyrimidine biosynthesis de novo in phytohemagglutinin-stimulated lymphocytes.

Authors:  K Ito; H Uchino
Journal:  J Biol Chem       Date:  1976-03-10       Impact factor: 5.157

7.  Severe combined immunodeficiency and adenosine deaminase deficiency.

Authors:  R Parkman; E W Gelfand; F S Rosen; A Sanderson; R Hirschhorn
Journal:  N Engl J Med       Date:  1975-04-03       Impact factor: 91.245

8.  Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes.

Authors:  F F Snyder; J Mendelsohn; J E Seegmiller
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

9.  Orotic aciduria in two unrelated patients with inherited deficiencies of purine nucleoside phosphorylase.

Authors:  A Cohen; G E Staal; A J Ammann; D W Martin
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

10.  Detection of the carrier state in combined immunodeficiency disease associated with adenosine deaminase deficiency.

Authors:  C R Scott; S H Chen; E R Giblett
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more
  2 in total

1.  Hypoxanthine is a checkpoint stress metabolite in colonic epithelial energy modulation and barrier function.

Authors:  J Scott Lee; Ruth X Wang; Erica E Alexeev; Jordi M Lanis; Kayla D Battista; Louise E Glover; Sean P Colgan
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

2.  Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.

Authors:  Adrian S Ray; Loren Olson; Arnold Fridland
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.